Microbiome Therapeutics

Microbiome therapeutics are a novel approach to restoring equilibrium within the microbiome, which in turn can evoke the required clinical response to suppress flares or promote remission. Multiple studies have shown the efficacy of fecal microbiota transplantation (FMT) to restore gut microbiota diversity, with positive outcomes for varied medical indications.

The past decade has seen significant development efforts for single-strain microbiota oral drug candidates, some of which are in the clinical stages of development. The human gut microbiome is comprised of trillions of microbes working together to modulate the metabolism, regulate the immune system and enable digestion.

Most healthy people harbor some 100-200 bacterial species in their gut, and these create a balanced ecosystem that supports well-being. An imbalance in this crucial ecosystem, however, is associated with infections, chronic disease and even neurological dysfunction.

An imbalance in the gut microbiome can be caused by many factors, such as diet, infections, genetics, and more.

Artboard 2-8

NuBiyota is pioneering the next generation of microbiota drug development. The company’s novel approach will revolutionize microbiome therapeutics, bringing multi-strain microbiota drugs to market for effective microbiota diversity restoration.

NuBiyota’s pipeline includes four clinical stage microbiome/microbiota therapeutic composition candidates for treatment of a host of indications, with an additional candidate in the beginning stages of R&D.